Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 1/2011

01-03-2011

Management of Right Ventricular Failure in the Era of Ventricular Assist Device Therapy

Author: Michael L. Craig

Published in: Current Heart Failure Reports | Issue 1/2011

Login to get access

Abstract

The increasing incidence of patients with advanced heart failure, limited donor availability, and continued advancements in the field of mechanical circulatory support have made implantation of left ventricular assist device therapy (LVAD) an attractive option for patients with end-stage heart failure. Perioperative right ventricular failure (RVF) occurs frequently in patients undergoing LVAD implantation and is associated with significant morbidity and mortality. This review will discuss the pathophysiology of RVF, recent efforts to risk-stratify patients preoperatively, and current preoperative, perioperative, and postoperative management strategies.
Literature
1.
Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345(20):1435-1443.CrossRefPubMed
2.
•• Miller LW, Pagani FD, Russell SD, et al.: Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007, 357(9):885-896. This is a landmark trial validating the use of continuous-flow HMII as an effective BTT therapy.
3.
•• Slaughter MS, Rogers JG, Milano CA, et al.: Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009, 361(23):2241-2251. This is a landmark trial comparing the HMII with the HM XVE. This trial validated the use of the HMII as DT option and demonstrated improved clinical outcomes with the HMII.CrossRefPubMed
4.
Kavarana MN, Pessin-Minsley MS, Urtecho J, et al.: Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 2002, 73(3):745-750.CrossRefPubMed
5.
Ochiai Y, McCarthy PM, Smedira NG, et al.: Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002, 106(12 Suppl 1):I198-202.PubMed
6.
Morgan JA, John R, Lee BJ, et al.: Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 2004, 77(3):859-863.CrossRefPubMed
7.
Furukawa K, Motomura T, Nose Y: Right ventricular failure after left ventricular assist device implantation: the need for an implantable right ventricular assist device. Artif Organs 2005, 29(5):369-377.CrossRefPubMed
8.
Dang NC, Topkara VK, Mercando M, et al.: Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 2006, 25(1):1-6.CrossRefPubMed
9.
• Fitzpatrick JR, 3 rd, Frederick JR, Hsu VM, et al.: Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008, 27(12):1286-1292. This was a large, single-center, retrospective study that used preoperative predictors of RVF to build a risk model.CrossRefPubMed
10.
• Matthews JC, Koelling TM, Pagani FD, Aaronson KD: The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008, 51(22):2163-2172. This was a large, single-center study in which preoperative variables were use to develop a right ventricular failure risk score.CrossRefPubMed
11.
Farrar DJ, Hill JD, Pennington DG, et al.: Preoperative and postoperative comparison of patients with univentricular and biventricular support with the thoratec ventricular assist device as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg 1997, 113(1):202-209.CrossRefPubMed
12.
Fukamachi K, McCarthy PM, Smedira NG, et al.: Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999, 68(6):2181-2184.CrossRefPubMed
13.
Santambrogio L, Bianchi T, Fuardo M, et al.: Right ventricular failure after left ventricular assist device insertion: preoperative risk factors. Interact Cardiovasc Thorac Surg 2006, 5(4):379-382.CrossRefPubMed
14.
Tsukui H, Teuteberg JJ, Murali S, et al.: Biventricular assist device utilization for patients with morbid congestive heart failure: a justifiable strategy. Circulation 2005, 112(9 Suppl):I65-72.PubMed
15.
• Fitzpatrick JR, 3 rd, Frederick JR, Hiesinger W, et al.: Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg 2009, 137(4):971-977. This was a large, single-center, retrospective study demonstrating that planned BiVAD support, when compared to delayed RVAD implantation, resulted in a significant improvement in survival.CrossRefPubMed
16.
Kaul TK, Fields BL: Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc Surg 2000, 8(1):1-9.CrossRefPubMed
17.
Santamore WP, Austin EH, 3 rd, Gray L, Jr.: Overcoming right ventricular failure with left ventricular assist devices. J Heart Lung Transplant 1997, 16(11):1122-1128.PubMed
18.
Chen JM, Levin HR, Rose EA, et al.: Experience with right ventricular assist devices for perioperative right-sided circulatory failure. Ann Thorac Surg 1996, 61(1):305-310; discussion 311-303.
19.
• Lee S, Kamdar F, Madlon-Kay R, et al.: Effects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function. J Heart Lung Transplant 2010, 29(2):209-215. This was a small, single-center study assessing the affects of the HMII on right ventricular function. This was the first such study with continuous-flow LVADs and demonstrated a low incidence of RVF.CrossRefPubMed
20.
Patel ND, Weiss ES, Schaffer J, et al.: Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg 2008, 86(3):832-840; discussion 832-840.
21.
• Drakos SG, Janicki L, Horne BD, et al.: Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 2010, 105(7):1030-1035. This was a large single-center study that resulted in creation of a risk model to predict RVF in patient population comprised of BTT-DT patients, the first to do so.CrossRefPubMed
22.
Flege JB, Jr., Wright CB, Reisinger TJ: Successful balloon counterpulsation for right ventricular failure. Ann Thorac Surg 1984, 37(2):167-168.CrossRefPubMed
23.
Skillington PD, Couper GS, Peigh PS, et al.: Pulmonary artery balloon counterpulsation for intraoperative right ventricular failure. Ann Thorac Surg 1991, 51(4):658-660.CrossRefPubMed
24.
Bhama JK, Kormos RL, Toyoda Y, et al.: Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant 2009, 28(9):971-976.CrossRefPubMed
25.
Sugiki H, Nakashima K, Vermes E, et al.: Temporary right ventricular support with Impella Recover RD axial flow pump. Asian Cardiovasc Thorac Ann 2009, 17(4):395-400.PubMed
26.
Loforte A, Montalto A, Lilla Della Monica P, Musumeci F: Simultaneous temporary CentriMag right ventricular assist device placement in HeartMate II left ventricular assist system recipients at high risk of right ventricular failure. Interact Cardiovasc Thorac Surg 2010, 10(6):847-850.CrossRefPubMed
27.
John R, Liao K, Kamdar F, et al.: Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices. J Thorac Cardiovasc Surg 2010, 140(2):447-452.CrossRefPubMed
28.
Wagner F, Dandel M, Gunther G, et al.: Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. Circulation 1997, 96(9 Suppl):II-291-296.
29.
Argenziano M, Choudhri AF, Moazami N, et al.: Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 1998, 65(2):340-345.CrossRefPubMed
30.
De Wet CJ, Affleck DG, Jacobsohn E, et al.: Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004, 127(4):1058-1067.CrossRefPubMed
31.
Tedford RJ, Hemnes AR, Russell SD, et al.: PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008, 1(4):213-219.CrossRefPubMed
32.
Kormos RL, Teuteberg JJ, Pagani FD, et al.: Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010, 139(5):1316-1324.CrossRefPubMed
Metadata
Title
Management of Right Ventricular Failure in the Era of Ventricular Assist Device Therapy
Author
Michael L. Craig
Publication date
01-03-2011
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 1/2011
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-010-0043-3

Other articles of this Issue 1/2011

Current Heart Failure Reports 1/2011 Go to the issue

Clinical Trial Report

Ivabradine in Heart Failure: To SHIFT or Not to SHIFT

ReviewPaper

Mechanical Bridge to Decision: What Are the Options for the Management of Acute Refractory Cardiogenic Shock?

ReviewPaper

Controversies in Cardiac Resynchronization Therapy: Do Sex Differences in Response Exist?

ReviewPaper

Novel Natriuretic Peptides: New Compounds and New Approaches

ReviewPaper

Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF

ReviewPaper

Immune Modulation in Heart Failure: Past Challenges and Future Hopes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits